Director Otello Stampacchia filed a Form 4 with the SEC on November 18, 2026, disclosing purchases and preferred-share conversions in Windward Bio Group AG common shares on November 16, 2026.

Key Highlights

  • Purchase transactions: Omega Fund VII, L.P. and Omega Fund VIII, L.P. each acquired 875,000 common shares at $17 per share on November 16, 2026, for a combined purchase of 1,750,000 shares.
  • Series A conversion: 1,262,628 Series A Preferred Shares held by Omega Fund VII and 1,262,626 held by Omega Fund VIII each converted into common shares on a 1-to-1 basis.
  • Series B conversion: 531,632 Series B Preferred Shares held by Omega Fund VII and 531,634 held by Omega Fund VIII each converted into common shares on a 1-to-1 basis.
  • Post-transaction ownership: Following all reported transactions, Omega Fund VII holds 2,669,260 common shares and Omega Fund VIII holds 2,669,260 common shares, both indirectly attributed to Stampacchia.
  • IPO conversion trigger: According to the filing, each Series A and Series B Preferred Share "automatically converted into the number of Common Shares on a 1 to 1 basis immediately prior to the closing of the Issuer's initial public offering."
  • Ownership disclaimed: Stampacchia, along with Claudio Nessi and Francesco Draetta, disclaims beneficial ownership of shares held by each fund "except to the extent of his pecuniary interest therein, if any."

Stampacchia's Transactions in Windward Bio Group AG at IPO

Director Otello Stampacchia reported multiple changes in beneficial ownership of Windward Bio Group AG (NASDAQ:WWB) common shares, all dated November 16, 2026, in a Form 4 filed November 18, 2026. The transactions encompass both open-market purchases coded "P" and conversions coded "C," each attributed indirectly to Stampacchia through his roles at Omega Fund VII, L.P. and Omega Fund VIII, L.P.

According to the filing, Omega Fund VII and Omega Fund VIII each purchased 875,000 common shares at a price of $17 per share. Separately, Series A Preferred Shares held by those funds - 1,262,628 by Omega VII and 1,262,626 by Omega VIII - converted into an equivalent number of common shares at a conversion price of $0. Series B Preferred Shares followed the same mechanism: 531,632 shares from Omega VII and 531,634 from Omega VIII converted into common shares at $0. The filing states these preferred share conversions occurred automatically on a 1-to-1 basis "immediately prior to the closing of the Issuer's initial public offering."

After all reported transactions, the filing shows Omega Fund VII beneficially owns 2,669,260 common shares and Omega Fund VIII also beneficially owns 2,669,260 common shares, both held indirectly. The ownership structure described in the filing flows through Omega Fund VII GP, L.P. and Omega Fund VIII GP, L.P. as sole general partners, and their respective GP Manager entities, of which Stampacchia, Claudio Nessi, and Francesco Draetta serve as directors. The form was signed by Scott Applebaum as Attorney-in-Fact on November 18, 2026.

What Was Disclosed

Otello Stampacchia, a director of Windward Bio Group AG, reported purchases of 875,000 common shares each through Omega Fund VII and Omega Fund VIII at $17, plus the automatic conversion of Series A and Series B Preferred Shares into common shares, all on November 16, 2026.